Healthcare / BiotechnologyKOSDAQKR
$2535.00
+140.00 (+5.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-28.7B · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$74.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.3%
↓Gross Margin
17.8%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+76.6%
FCF CAGR
—
FCF margin
-402.8%
FCF / Net income
2.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.84B · net income $-12.07B · FCF $-35.61B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $8.84B | $8.84B | $4.17B | — | $480.0M | $909.1M |
| Net Income | $-12.07B | $-12.07B | $-12.26B | $-11.61B | $-22.86B | — |
| EBITDA | $-9.41B | $-9.41B | $-9.05B | $-7.68B | $-18.64B | — |
| EPS | -474.00 | -474.00 | -743.00 | -1078.00 | -2052.77 | — |
| Gross Margin | 17.8% | 17.8% | 16.9% | — | 32.4% | 100.0% |
| Operating Margin | -128.3% | -128.3% | -287.6% | — | -3106.5% | — |
| Net Margin | -136.5% | -136.5% | -294.3% | — | -4763.5% | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.37 | 0.37 | 0.26 | 0.30 | 0.53 | — |
| Cash Flow | ||||||
| Free Cash Flow | $-35.61B | $-35.61B | $-28.73B | $-18.40B | $-13.42B | — |
| Returns | ||||||
| ROE | -16.3% | -16.3% | -23.9% | -28.7% | -101.9% | — |
| Valuation | ||||||
| P/B | 0.87 | 0.87 | 1.73 | 1.21 | 5.40 | — |
| Growth & Yield | ||||||
| Revenue Growth | 112.3% | 112.3% | — | — | -47.2% | — |
| EPS Growth | 36.2% | 36.2% | 31.1% | 47.5% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-71.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-743.00 → -474.00
Residual
-71.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.